Tag Archives: PBCAR0191

Precision’s PBCAR0191 to Target Autologous CD19 CAR-T Relapsed Patients; PBCAR269A to Be Used with Nirogacestat; ASH 2021 Day 1 Precision Investor Event

On Saturday, December 11, Precision held their investor event (press release / presentation) discussing clinical updates from their CAR-T pipeline at ASH 2021. Celltelligence provides insights on how Precision could leverage the advancement of autologous CD19 CAR-Ts into earlier lines of therapy to target a growing, yet less competitive, patient population.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision’s PBCAR20A Deprioritized; TCR2 Tx Focuses on Building up Their Manufacturing Capacity in the US; Precision and TCR2 Tx Q3 2021 Earnings Summaries

On Wednesday, November 10, Precision BioSciences reported their Q3 2021 financial results (press release) highlighting the deprioritization of PBCAR20A (CD20 CAR-T) in NHL. On the same day, TCR2 Tx released their Q3 2021 financial results (press release) highlighting gavo-cel’s (TC-210; mesothelin TRuC-T) anticipated Ph2 trial initiation in early 2022 and their manufacturing capacity expansion at ElevateBio BaseCamp in Cambridge, MA.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision BioSciences Provides No Major Clinical Updates; Precision Q2 2021 Earnings Call Summary

On Thursday, August 12, Precision BioSciences reported their Q2 2021 results (press release) highlighting data presented at ASCO 2021 from PBCAR0191’s Ph1/2a trial in r/r NHL and ALL. Furthermore, management confirmed the dosing of the first patient in both PBCAR19B (stealth CD19 CAR-T) and PBCAR269A (BCMA CAR-T) programs. Below, Celltelligence provides details on Precision’s upcoming milestones.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision Improves Response Rates With an Enhanced LD; Is ALLO-501A’s Efficacy Good Enough? How Will CRISPR Tx Compare to Precision and Allogene in the CD19 CAR-T Space? ASCO 2021 Day 2

On the second day of ASCO 2021, two key clinical updates were presented from Precision BioSciences and Allogene, while CRISPR Therapeutics discussed their clinical trial design for CTX110. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Updated Interim Results from PBCAR0191’s Ph1/2a Trial; New Details Provided for PBCAR19B Stealth CAR-T Program; Precision’s Pre-ASCO CD19 Event

On Friday, June 4, Precision BioSciences held their PBCAR0191 CD19 virtual update event (webcast / presentation). Management reported updated results on PBCAR0191’s Ph1/2a trial in r/r NHL while providing further details on their CD19 stealth cell program (PBCAR19B). Below, Celltelligence provides insights on the effect of Precision’s enhanced lymphodepletion (eLD) regimen to improve PBCAR0191’s efficacy while comparing PBCAR0191’s dosing strategy and lymphodepletion approach with key competitor Allogene.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision BioSciences Provides No Major Clinical Updates; Q1 2021 Earnings Call Summary

On Thursday, May 13, Precision BioSciences released their Q1 2021 results (press release) highlighting their recent reacquisition of all global rights for their allogeneic CAR-T program from Servier. No major clinical, regulatory, or corporate updates were provided. Below, Celltelligence provides details on Precision’s upcoming milestones.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Precision Regains Control of Their Allogeneic CAR-T Pipeline and Shifts Focus to their Stealth Cell Program; Alan List Joins Precision as CMO

On Thursday, April 15, Precision BioSciences announced (press release / presentation) that they have entered into a Program Purchase Agreement to reacquire all global rights for their allogeneic CAR-T program. Furthermore, Alan List was appointed (press release) as the company’s new Chief Medical Officer (CMO) and a member of the senior leadership team. Below, Celltelligence provides insights on Precision’s decision to fully control their allogeneic pipeline and how Precision’s new senior leadership could potentially accelerate stealth cell clinical development.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Interim Results from PBCAR0191’s Ph1/2a Trial; Updated Clinical Strategies to Improve Response; New Details Disclosed for PBCAR19B Stealth CAR-T; Precision’s Pre-ASH Investor Call Summary

On Friday, December 4, Precision reported interim results from their PBCAR0191 Ph1/2a trial, an allogeneic CD19 CAR-T in r/r NHL and ALL, and held an investor webcast (press release / presentation). Management confirmed that PBCAR19B, a next generation CD19 “stealth cell” CAR-T, is expected to enroll patients in H1 2021. Below, Celltelligence provides insights into PBCAR0191’s lymphodepletion regimens and how their approach differs from key allogeneic competitor Allogene.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.